isomethyleugenol has been researched along with Neuroectodermal Tumors, Primitive in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Achari, RB; Das, A; Gehani, A; Hawkins, C; Ho, B; Huang, A; Lamichhane, R; Ramaswamy, V; Roy, P; Sukumaran, RK; Tabori, U; Zameer, L | 1 |
| Bilbao, JM; Del Maestro, RF; Fazl, M; Guiot, MC; Oh, J; Perry, JR; Tsao, MN | 1 |
2 other study(ies) available for isomethyleugenol and Neuroectodermal Tumors, Primitive
| Article | Year |
|---|---|
A novel central nervous system embryonal tumor successfully treated with multi-modal therapy highlights limitation of methylation-based tumor classification.
Topics: Central Nervous System; Central Nervous System Neoplasms; Humans; Methylation; Neoplasms, Germ Cell and Embryonal; Neuroectodermal Tumors, Primitive | 2022 |
Recurrent PNET with MGMT methylation responds to temozolomide.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Humans; Magnetic Resonance Imaging; Male; Methylation; Neuroectodermal Tumors, Primitive; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide | 2009 |